|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers- Review显示文摘Venous thromboembolism event(VTE) is a common and morbid complication in cancer patients. Patients with gastrointestinal cancers often suffer from symptomatic or incidental splanchnic vein thrombosis, impaired liver function and/or thrombocytopenia. These characteristics require a thorough risk/benefit evaluation for individual patients. Considering the risk factors for the development of VTE and bleeding events in addition to recent study results may be helpful for correct initiation of primary pharmacological prevention and treatment of cancer-associated thrombosis(CAT), preferably with low molecular weight heparins(LMWH). Whereas thromboprophylaxis is most often recommended in hospitalized surgical and non-surgical patients with malignancy, there is less agreement as to its duration. With regard to ambulatory cancer patients, the lack of robust data results in low grade recommendations against routine use of anticoagulant drugs. Anticoagulation with LMWH for the first months is the evidence-based treatment for acute CAT, but duration of secondary prevention and the drug of choice are unclear. Based on published guidelines and literature, this review will focus on prevention and treatment strategies of VTE in patients with gastrointestinal cancers. | Hanno Riess Piet Habbel Anja Jühling Marianne Sinn Uwe Pelzer | 2016 | World Journal of Gastrointestinal Oncology2016，8，3： | 9 |
| 2 | Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer显示文摘 | Philippe Rougier Hanno Riess Robert Manges Petr Karasek Yves Humblet Carlo Barone Armando Santoro Sylvie Assadourian Laurence Hatteville Philip A. Philip | 2013 | European Journal of Cancer2013，，12： | 4 |
| 3 | Perioperative treatment options in resectable pancreatic cancer-how to improve long-term survival显示文摘Surgery remains the only chance of cure for pancreatic cancer, but only 15%-25% of patients present with resectable disease at the time of primary diagnosis. Important goals in clinical research must therefore be to allow early detection with suitable diagnostic procedures, to further broaden operation techniques and to determine the most effective perioperative treatment of either chemotherapy and/or radiation therapy. More extensive operations involving extended pancreatectomy, portal vein resection and pancreatic resection in resectable pancreatic cancer with limited liver metastasis, performed in specialized centers seem to be the surgical procedures with a possible impact on survival. After many years of stagnation in pharmacological clinical research on advanced pancreatic ductal adenocarcinomas(PDAC)- since the approval of gemcitabine in 1997- more effective cytotoxic substances(nab-paclitaxel) and combinations(FOLFIRINOX) are now available for perioperative treatment. Additionally, therapies with a broader mechanism of action are emerging(stroma depletion, immunotherapy, antiinflammation), raising hopes for more effective adjuvant and neoadjuvant treatment concepts, especially in the context of 'borderline resectability'. Only multidisciplinary approaches including radiology, surgery, medical and radiation oncology as the backbones of the treatment of potentially resectable PDAC may be able to further improve the rate of cure in the future. | Marianne Sinn Marcus Bahra Timm Denecke Sue Travis Uwe Pelzer Hanno Riess | 2016 | World Journal of Gastrointestinal Oncology2016，8，3： | 3 |
| 4 | The cellular and molecular basis of hyperthermia显示文摘 | Bert Hildebrandt Peter Wust Olaf Ahlers Annette Dieing Geetha Sreenivasa Thoralf Kerner Roland Felix Hanno Riess | 2002 | Critical Reviews in Oncology and Hematology2002，，： | 3 |
| 5 | Hyperthermia in combined treatment of cancer显示文摘 | P Wust B Hildebrandt G Sreenivasa B Rau J Gellermann H Riess R Felix PM Schlag | 2002 | Lancet Oncology2002，，8： | 2 |
| 6 | Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group显示文摘 | Uwe Pelzer Ingo Schwaner Jens Stieler Mathias Adler J?rg Seraphin Bernd D?rken Hanno Riess Helmut Oettle | 2011 | European Journal of Cancer2011，，11： | 2 |
| 7 | Synthesis of poly (methyl methacrylate)-g- poly(dimethyl siloxane) graft copolymers via a miniemulsion process 显示文摘 | Calderara F Riess G | 2001 | Polymer Bulletin2001，47，： | 1 |
| 8 | Clinical experiences with magnetic drug targeting:a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors显示文摘 | Lubbe AS Bergemann C Riess H | 1996 | Cancer Res1996，56，20： | 1 |
| 9 | Experimental investigation of turbulent wake - blade interaction in axial compres- sors显示文摘 | Sentker A Riess W | 2000 | International Journal of Heat and Fluid Flow2000，21，3： | 1 |
| 10 | Clinical experience with magnetic drug targeting显示文摘 | Lubbe A S Bergeman C Riess H | 1996 | Cancer Research1996，56，： | 1 |
| 11 | Analysis of CD95 threshold signaling: triggering of CD95 ( FAS/APO - 1 ) at low concentrations primarily results in survival signaling 显示文摘 | Krueger A Baumann S Riess D | 2007 | J Biol Chem2007，282，13： | 1 |
| 12 | Why HIV Infections Have Increased Among Men Who Have Sex with Men and What to Do About It: Findings from California Focus Groups显示文摘 | Stephen F. Morin Karen Vernon John (Jay) Harcourt Wayne T. Steward Jonathan Volk Thomas H. Riess Torsten B. Neilands Marisa McLaughlin Thomas J. Coates | 2003 | AIDS and Behavior2003，，4： | 1 |
| 13 | Per - and polyfluorinated substances (PFASs) :Environmental challenges 显示文摘 | KRAFFT M P RIESS J G | 2015 | Curt Opin Colloid Interface Sci2015，20，3： | 1 |
| 14 | Highly fluorinated systems for oxygen transport diagnosis and drug delivery 显示文摘 | Riess J G | 1999 | Colloid and Surface A1999，，84： | 1 |
| 15 | Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery 显示文摘 | RIESS JG | 2005 | Artif Cells Blood Substit hnmobil Biotechnol2005，33，1： | 1 |
| 16 | 14-3-3 Proteins in the Nervous System显示文摘 | BERG D VIOLZMANN C RIESS O | 2003 | Nat Rev Neurosci(S1471- 0048)2003，4，： | 1 |
| 17 | Differential increase of mitochondrial matrix volume by sevoflurane in isolated cardiac mitochondria显示文摘 | Riess ML Costa AD Carlson R Jr | 2008 | Anesth Analg2008，106，： | 1 |
| 18 | Dual exposure to sevoflurane improves anesthetic preconditioning in intact hearts 显示文摘 | Riess ML Kevin LG Camara AK | 2004 | Anesthesiology2004，100，3： | 1 |
| 19 | Preconditioning with sevoflurane reduces changes in nicotinamide adenine dinu- cleotide during ischemia-reperfusion in isolated hearts: reversal by 5-hydroxydecanoic acid显示文摘 | Riess M L Novatija E Camara A K | 2003 | Anesthesiology2003，98，2： | 1 |
| 20 | Mixed ionic-electronic conductors-material properties and applications显示文摘 | RIESS I | 2003 | Solid State Ionics2003，157，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员